Published in Clin Cancer Res on October 01, 2005
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res (2008) 1.14
Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv (2009) 1.02
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.01
WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer (2011) 1.01
Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer (2009) 0.98
Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging (2014) 0.95
A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys (2010) 0.92
Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs (2015) 0.86
Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv (2010) 0.85
State-of-the-art approach for bone sarcomas. Eur J Orthop Surg Traumatol (2014) 0.82
Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape. Cancer Biother Radiopharm (2010) 0.82
Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer (2010) 0.79
Genistein sensitizes sarcoma cells in vitro and in vivo by enhancing apoptosis and by inhibiting DSB repair pathways. J Radiat Res (2016) 0.77
Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma. J Bone Oncol (2013) 0.75
Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. Cancer Biother Radiopharm (2015) 0.75
Beyond Palliation: Therapeutic Applications of (153)Samarium-EDTMP. Clin Exp Pharmacol (2013) 0.75
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer (2007) 2.62
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas (2010) 1.90
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol (2005) 1.84
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol (2002) 1.79
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med (2002) 1.60
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol (2005) 1.55
Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer (2007) 1.54
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol (2003) 1.52
The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas (2010) 1.51
Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. Pediatr Blood Cancer (2011) 1.42
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer (2007) 1.41
Assessing the health care needs of adolescent and young adult cancer patients and survivors. Cancer (2006) 1.39
Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. J Comput Assist Tomogr (2007) 1.38
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. Am J Hematol (2014) 1.23
Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer (2008) 1.22
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm (2007) 1.22
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med (2007) 1.19
Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst (2011) 1.18
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol (2012) 1.09
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun (2007) 1.05
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma (2006) 1.02
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma (2008) 1.02
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun (2007) 0.96
The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol (2012) 0.94
Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion (2008) 0.93
Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab (2002) 0.90
Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol (2002) 0.88
18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid (2008) 0.87
Outcomes and metrics: measuring the impact of a comprehensive adolescent and young adult cancer program. Cancer (2011) 0.87
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol (2002) 0.86
Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma (2014) 0.85
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol (2013) 0.84
Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma. J Vasc Interv Radiol (2009) 0.83
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun (2007) 0.83
Patterns of fatigue in adolescents receiving chemotherapy. Oncol Nurs Forum (2010) 0.83
Meningitis caused by lymphocytic choriomeningitis virus in a patient with leukemia. J Pediatr Hematol Oncol (2008) 0.83
Measuring granulocyte and monocyte accumulation at malignant lymphoma sites. J Clin Oncol (2008) 0.82
Retrieval yield of total and messenger RNA in mesenchymal tissue ex vivo. Clin Orthop Relat Res (2003) 0.81
Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A (2004) 0.80
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med (2009) 0.80
Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. Cancer Med (2015) 0.80
Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr (2003) 0.80
Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med (2007) 0.79
Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism. World J Surg (2006) 0.79
Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun (2011) 0.79
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol (2010) 0.79
Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G). Eur J Haematol (2007) 0.79
18F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol (2009) 0.79
Progress in gene therapy for prostate cancer. Front Oncol (2012) 0.78
Tacrolimus with mini-methotrexate as prophylaxis for graft-versus-host disease in pediatric patients after allogeneic peripheral blood stem cell transplant or bone marrow transplant. J Pediatr Hematol Oncol (2008) 0.78
The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol (2009) 0.78
Novel splice site mutations in the gamma glutamyl carboxylase gene in a child with congenital combined deficiency of the vitamin K-dependent coagulation factors (VKCFD). Pediatr Blood Cancer (2009) 0.77
Outcome prediction in heart failure with atrial fibrillation: relative role of left ventricular ejection fraction and neurohormonal measures. J Nucl Cardiol (2013) 0.77
Cerebral venous sinus thrombosis in pediatric cancer patients: long-term neurological outcomes. J Pediatr Hematol Oncol (2013) 0.76
Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol (2009) 0.76
Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk Lymphoma (2006) 0.76
Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplant (2005) 0.75
Empiric treatment of protracted idiopathic purpura fulminans in an infant: a case report and review of the literature. J Med Case Rep (2011) 0.75
Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer (2006) 0.75
Assessment of Lymphoma Therapy Using (18)F-FDG PET. J Nucl Med (2002) 0.75
Racial and ethnic differences in hospice enrollment among children with cancer. Pediatr Blood Cancer (2013) 0.75
Diffuse large B-cell lymphoma in an adolescent female presenting with Epstein-Barr virus-driven hemophagocytic lymphohistiocytosis: a case report. J Med Case Rep (2012) 0.75
Transient neonatal acquired von Willebrand syndrome due to transplacental transfer of maternal monoclonal antibodies. Pediatr Blood Cancer (2009) 0.75
Health-related quality of life in children and young adults with post-thrombotic syndrome: results from a cross-sectional study. Pediatr Blood Cancer (2014) 0.75
Congenital amegakaryocytic thrombocytopenia: a case report of pediatric twins undergoing matched unrelated bone marrow transplantation. J Pediatr Hematol Oncol (2015) 0.75
Autoimmune Hemolytic Anemia in Children: Mayo Clinic Experience. J Pediatr Hematol Oncol (2016) 0.75
Pelvic pseudotumor and pseudoaneurysm in a pediatric patient with moderate hemophilia B: successful management with arterial embolization and surgical excision. Pediatr Blood Cancer (2011) 0.75
Lemierre Syndrome: A Retrospective Study of the Role of Anticoagulation and Thrombosis Outcomes. Acta Haematol (2016) 0.75
Development and initial validation of a questionnaire to diagnose the presence and severity of post-thrombotic syndrome in children. Pediatr Blood Cancer (2011) 0.75
Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience. J Pediatr Hematol Oncol (2012) 0.75
Impatient patients. A new mobile app provides health care information on the move. Mark Health Serv (2011) 0.75
A prospective, randomized crossover study comparing direct inspection by light microscopy versus projected images for teaching of hematopathology to medical students. Anat Sci Educ (2013) 0.75
Postradiation dermatofibrosarcoma protuberans in a patient with Wilms tumor. J Pediatr Hematol Oncol (2011) 0.75
Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer (2009) 0.75
A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant. J Pediatr Hematol Oncol (2017) 0.75
Bacterial endocarditis and septic arthritis in a patient with severe hemophilia A: a case report. J Pediatr Hematol Oncol (2009) 0.75
Molecular cytogenetic characterization of a case of Müllerian adenosarcoma. Cancer Genet Cytogenet (2004) 0.75
A retrospective review of pediatric antiphospholipid syndrome and thrombosis outcomes. Blood Coagul Fibrinolysis (2017) 0.75